November 2006- Volume 2, Issue 11
November 2006
In this Issue
Editor's Focus
Metabolomics: Clearing the logjam for biomarkers
Metabolomics: Clearing the logjam for biomarkers
Although many analytical chemists and biochemists will claim they have been practicing the science of identifying small molecules in biological matrices long before 2000, most agree that as a robust discovery tool, the technology is new and rapidly evolving. Since then, there has been an explosion of papers describing the technology as well as a significant number of papers using the technology for the discovery of biomarkers.
Genomics & Proteomics
Cogenics, Algynomics team up on pain panel
Cogenics, Algynomics team up on pain panel
Genetic markers to allow clients to examine the genetic basis or underpinnings of human pain.
Enzyme market penetration
Enzyme market penetration
Millipore’s global reach will help get JPT’s enzyme line worldwide customers
Amgen acquires Avidia for $290 million
Amgen acquires Avidia for $290 million
Deal sees biotech giant pick up Avimer proteins platform.
Global News
Teva, Protalix collaborate on two biopharmaceuticals
Teva, Protalix collaborate on two biopharmaceuticals
Companies to develop two proteins using Protalix’s plant cell culture platform.
Neurotech organization to advance brain, nervous system therapies
Neurotech organization to advance brain, nervous system therapies
Companies form a new trade association called the Neurotechnology Industry Organization (NIO).
Gilead Sciences to acquire Myogen for $2.5 billion
Gilead Sciences to acquire Myogen for $2.5 billion
Myogen will become a wholly-owned subsidiary of Gilead.
Microarrays have big future in store
Microarrays have big future in store
SNP market at about $400 million; in next 5 years to $1 billion.
Research & Development
NGI co-develops R&D office, incubator with U. Iowa
NGI co-develops R&D office, incubator with U. Iowa
Plans to build a new 80,000-sq.ft research center and business incubator.
Yale, NFCR launch cancer drug research center
Yale, NFCR launch cancer drug research center
Five-year, $750,000 grant to develop new beta-peptide inhibitors.
Rx3 recieves two NIH grants
Rx3 recieves two NIH grants
Company wants to fight drug-resistant organisms.
Tag-teaming tuberculosis
Tag-teaming tuberculosis
Cumbre and TB Alliance announce partnership to develop new TB agents
Cardiovascular collaboration
Cardiovascular collaboration
Servier taps Plexxikon for non-peptidic rennin inhibitor project
Informatics
3-D map of mouse brain gene expression
3-D map of mouse brain gene expression
The brain atlas details more than 21,000 genes at the cellular level.
BioIT Alliance targets biomarkers
BioIT Alliance targets biomarkers
BioIT Alliance begins the Biomarker Project and recruits Agilent.
Scientists link gene behavior with disease and drugs
Scientists link gene behavior with disease and drugs
Connectivity Map opens doors to early prediction of effective or detrimental drug candidates.
Bundled biomarker deal
Bundled biomarker deal
InforSense, Thermo OEM agreement may accelerate protein biomarker discovery.
Automation & Instrumentation
Is it easy being green?
Is it easy being green?
CEM, EPA collaborate on chemistry scale-up
Beckman Acquires Lumigen
Beckman Acquires Lumigen
Chemiluminescent chemistries to be used in Beckman Coulter’s Access immunoassay systems.
NimbleGen signs license deal with Affymetrix
NimbleGen signs license deal with Affymetrix
NimbleGen looking to diversify from its current service model.
